The biotech contrarian

Joseph Cortright" />Joseph Cortright If you've been to any Biotechnology Industry Organization (BIO) convention in the past several years, you'll have noticed dozens of booths staffed by economic development officials from all over the world, all working to lure biotech investment in their regions. Biotech, many seem to believe, is one of the most important drivers of growth and jobs. Joe Cortright disagrees. The economist and vice president of Impresa Consulting in Portland, Oreg

Written byKent Steinriede
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

If you've been to any Biotechnology Industry Organization (BIO) convention in the past several years, you'll have noticed dozens of booths staffed by economic development officials from all over the world, all working to lure biotech investment in their regions. Biotech, many seem to believe, is one of the most important drivers of growth and jobs.

Joe Cortright disagrees. The economist and vice president of Impresa Consulting in Portland, Oregon, calls biotechnology an "idea virus" that has infected public officials and economic development agencies. "There's a lot of boosterism out there," Cortright says. "The fascination with biotech says a lot about the group-think mentality in economic development." It also says a lot about the relationship between economic consultants and their clients, he says: "People don't pay consultants to tell them what they can't do."

Cortright gained notoriety after co-authoring a 2002 Brookings Institution report, "Signs of Life: The Growth of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies